Zhizhang Yin

Statistics

Publications

Citations

1.2K

H-Index

Active since

1997

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Icahn School of Medicine at Mount Sinai

Discovery Laboratories (United States)

Lovelace Respiratory Research Institute

Pfizer (United States)

Zhizhang Yin is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in life sciences, pharmacology, and protein kinase inhibitors.

Publications per year

1997–2024

Publications

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Matthew Fell, Christian Mirescu, Kallol Basu et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 337 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Smad proteins act in combination with synergistic and antagonistic regulators to target Dpp responses to theDrosophila mesoderm

Xiaolei Xu, Zhizhang Yin, John B. Hudson et al. · Genes & Development · 1998 · 250 citations · Full text

Life Sciences, Developmental Biology, Molecular Biology +17

Regulation of the Twist target gene tinman by modular cis-regulatory elements during early mesoderm development

Zhizhang Yin, Xiao-Lei Xu, Manfred Frasch · Development · 1997 · 186 citations

Life Sciences, Biology, Genetics +17

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

Jack D. Scott, Duane E. DeMong, Thomas J. Greshock et al. · Journal of Medicinal Chemistry · 2017 · 148 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits

Marco A. S. Baptista, Kalpana Merchant, Ted Barrett et al. · Science Translational Medicine · 2020 · 130 citations

Medicine, Pharmacology, Pharmacotherapy +9

1–5 of 10